IS THE A IN ANDA BEGINNING TO MEAN ANTITRUST?

Robins Kaplan LLP
Contact
The Abbreviated New Drug Application (ANDA) process is one of the hottest areas of intellectual property disputes among companies today. But the Federal Circuit’s recent decision in Tyco Healthcare v. Mutual Pharmaceutical is beginning to demonstrate that the intersection between intellectual property law and antitrust is growing. Martin Lueck, Partner and Chairman for Robins, Kaplan, Miller & Ciresi L.L.P., sits down with Seth Northrop to discuss the overlap and how it may impact ANDA cases going forward.
Embed
Copy

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP
Contact
more
less

Robins Kaplan LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide